Experimental 'Living Drug' tested to halt Body's Self-Attack

This early-stage study is testing the safety and initial effects of a therapy called RD06-04, a type of CAR-T cell injection, in adults with active autoimmune diseases like lupus, scleroderma, and vasculitis. The therapy involves collecting a patient's own immune cells, modifying them in a lab to target a protein called CD19, and reinfusing them to potentially reset the faulty immune system. The trial is currently suspended and will closely monitor 12 participants for side effects and any signs that the treatment helps control their disease.